Green Cross Corp
KRX:006280
Green Cross Corp
Revenue
Green Cross Corp
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Green Cross Corp
KRX:006280
|
Revenue
₩1.7T
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Celltrion Inc
KRX:068270
|
Revenue
₩3.6T
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
22%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Revenue
₩373B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Revenue
₩350.1B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
30%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Revenue
₩102.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
29%
|
CAGR 10-Years
31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Revenue
₩33.4B
|
CAGR 3-Years
84%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Green Cross Corp
Glance View
Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.
See Also
What is Green Cross Corp's Revenue?
Revenue
1.7T
KRW
Based on the financial report for Dec 31, 2024, Green Cross Corp's Revenue amounts to 1.7T KRW.
What is Green Cross Corp's Revenue growth rate?
Revenue CAGR 10Y
6%
Over the last year, the Revenue growth was 3%. The average annual Revenue growth rates for Green Cross Corp have been 3% over the past three years , 4% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet